More vaccinated deaths than unvaccinated deaths from covid (US)

OskarSwindler
Published on Nov 26, 2022
58% of covid US deaths now in the vaccinated

Kaiser Family Foundation vice president Cynthia Cox

https://www.cdc.gov/vaccines/covid-19/effectiveness-research/protocols.html

https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/monitoring.html

https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm

https://www.washingtonpost.com/politics/2022/11/23/vaccinated-people-now-make-up-majority-covid-deaths/

58% of coronavirus deaths in August were people who were vaccinated or boosted

(people who had completed at least their primary series of vaccines)

Therefore 42% coronavirus deaths in August were people who were unvaccinated

First time there were more deaths covid deaths in the vaccinated versus the unvaccinated

https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5

In September 2021
Vaccinated people, 23% of coronavirus fatalities

In January and February 2022

Vaccinated people, 42% of coronavirus fatalities

We can no longer say this is a pandemic of the unvaccinated

(who conducted the analysis on behalf of the Post)

https://www.cdc.gov/mmwr/volumes/71/wr/mm7144a3.htm?s_cid=mm7144a3_w

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022

On August 31, 2022

FDA authorized bivalent, Pfizer-BioNTech and Moderna

mRNA encoding the spike protein from original strain of SARS-CoV-2,

and from Omicron BA.4 and BA.5

Advisory Committee on Immunization Practices (ACIP) recommended,

all persons ≥12 years receive an age-appropriate bivalent mRNA booster dose

v-safe

a voluntary smartphone-based U.S. safety surveillance system,

established by CDC to monitor adverse events after COVID-19 vaccination

As of 3rd October, 10 million users

https://icandecide.org/press-release/breaking-news-ican-obtains-cdc-v-safe-data/

Vaccine Adverse Event Reporting System (VAERS)

Total data, August 31–October 23, 2022

14.4 million received a bivalent Pfizer-BioNTech

8.2 million adults (≥18 years) a bivalent Moderna booster dose

v-safe, among the 211,959 registrants (aged ≥12 years)

August 31–October 23, 2022

Reported in the week after vaccination

Injection site reactions, 60.8%

Systemic reactions, 54.8%

Fewer than 1% of v-safe registrants reported receiving medical care

Vaccine Adverse Event Reporting System (VAERS)

5,542 reports of adverse events after bivalent booster vaccination (≥12 years)

95.5% of reports were nonserious

4.5% were serious events

Health care providers and patients can be reassured that adverse events reported after a bivalent booster dose are consistent with those reported after monovalent doses.

Relative risk

Absolute risk not given

Health impacts after COVID-19 vaccination are less frequent and less severe than those associated with COVID-19 illness (2).

Relative risk

Absolute risk not given


This is their Reference 2

Block JP, Boehmer TK, Forrest CB, et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination—PCORnet, United States, January 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:517–23. https://doi.org/10.15585/mmwr.mm7114e1 PMID:35389977

myocarditis; myocarditis or pericarditis; and myocarditis, pericarditis, or MIS,

within 7-day or 21-day risk windows after the index date

Comparisons between after vaccine and after infection

Relative risk

Absolute risk not given

Review of v-safe Data

During August 31–October 23, 2022

211,959 v-safe registrants had a bivalent booster

1,464 (0.7%) were aged 12–17 years

68,592 (32.4%) were aged 18–49 years

59,209 (27.9%) were aged 50–64 years

82.694 (39.0%) were aged ≥65 years

Fourth dose

96,241; 45.4%

Fifth dose

106,423; 50.2%

In the week after receipt of the bivalent booster dose

Local injection site reactions

49.7% among aged ≥65

72.9% among aged 18–49

Systemic reactions

43.5% among aged ≥65

67.9% among aged 18–49

Systemic symptoms

Fatigue (30.0%–53.1%)

Headache (19.7%–42.8%)

Myalgia (20.3%–41.3%)

Fever (10.2%–26.3%)

Reported inability to complete normal daily activities

10.6% among aged ≥65 years

19.8% among aged 18–49 years

Receipt of medical care

Reported by 0.8% of registrants

Share Video

  • 560 x 315
  • 640 x 360
  • 853 x 480
  • 1280 x 720

Add to

Flag Video

Rate video

Rate video

DISCLAIMER

The content presented in this stream and/or video may be satirical in nature for entertainment purposes. It may contain realistic scenarios that may include themes of racism, anti-semitism, anti-LGBT sentiment and even elements such as death threats, all purely in the context of parody. In addition, this content may depict or refer to acts of violence in a satirical manner. Shock factor is a common and deliberate element used in these displays to emphasise the satirical message. By continuing to view this content, you acknowledge that you understand the satirical nature of this content, including the depiction of violence and the use of shock factor, and agree that you will not use or interpret this content outside of its intended context. Please remember that humour and satire are complex; they are not intended to belittle or demean, but to engage and challenge social norms through exaggeration. If you have any concerns about content, please feel free to engage in constructive dialogue or report issues to GTV staff.

Up next